News Archive

2011-12-16
Berlin Heart receives FDA Approval
  Berlin Heart announced today that the FDA has granted "Humanitarian Device Exemption” (HDE) approval of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD). The...

2011-08-26
AFFINITY™ CP with CBAS® FDA cleared
This July, Medtronic received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the AFFINITY™ CP Centrifugal Blood Pump with the Carmeda® BioActive Surface coating...

2011-06-02
GORE® Hybrid Vascular Graft launched
The GORE® Hybrid Vascular Graft is now commercial availiable in the United States. The Gore device expands treatment options and improves blood flow for dialysis access patients...

2011-02-22
CE Mark for PROPATEN® for Hemodialysis
W. L. Gore & Associates (Gore) announced the GORE® PROPATEN® Vascular Graft for hemodialysis access has received CE Mark. The GORE PROPATEN Vascular Graft utilizes the...

2010-10-13
Propaten® beats standard ePTFE grafts
GORE® PROPATEN® vascular grafts featuring the Carmeda® bioactive surface technology shows advantages compared with standard ePTFE grafts. The new data, from...

2010-10-08
Carmeda featured at Biointerface 2010
Carmeda, a world leader in blood compatible coatings for medical devices will be featured in the upcoming Biointerface 2010 meeting.   The meeting is organized by the...

2010-07-05
New product movie!
Click here to watch the new CBAS product movie.

2009-11-24
More than 400 scientific publications
The use of the Carmeda® Bioactive surface technology continue to increase every year and so are the number of published scientific reports, which features the technology...

2008-05-08
Heparin from Carmeda is not contaminated
Heparin from Carmeda is not contaminated In response to the Medtronic News Release dated May 7, 2008 regarding a voluntary and precautionary recall of selected products featuring...

2006-11-17
FDA clears GORE PROPATEN Vascular Graft
The U.S. Food & Drug Administration (FDA) has given W. L. Gore & Associates, Inc. (GORE) clearance to market its GORE PROPATEN Vascular Graft for peripheral use, including lower-limb...